Stalicla

The combination of STALICLA and Firefly Neurosciences’s machine learning platforms and know-how will further strengthen the development of precision medicine for these patients.   Geneva, Switzerland – 27 March 2023, STALICLA SA and Firefly Neuroscience today announced a partnership to further validate EEG-based biomarkers in biologically enriched subgroups of patients with Autism Spectrum Disorder (ASD). …

STALICLA and Firefly Neuroscience enter Partnership Agreement for the Development of Electroencephalogram (EEG) as a Biomarker for Subgroups of Patients with ASD Read More »

STALICLA signs Cooperative Research and Development Agreement (CRADA) with US National Institute on Drug Abuse (NIDA) to cover Phase 3 development of mavoglurant in cocaine use disorder. Agreement follows STALICLA’s recent in-licencing of mavoglurant from Novartis.   Geneva, Switzerland – 8 March 2023, STALICLA SA, a clinical stage biotech advancing the first precision neurobiology platform …

STALICLA signs Cooperative Research and Development Agreement (CRADA) with US National Institute on Drug Abuse (NIDA) to cover Phase 3 development of mavoglurant in cocaine use disorder Read More »

La société genevoise a racheté à Novartis une molécule. Un coup qui lui permet d’accélérer son développement et de percer sur le marché américain   READ MORE

The 41st Annual Healthcare Conference will take place on January 9-12, 2023 in San Francisco, CA. This premier conference is the largest and most informative healthcare investment symposium in the industry which connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.   READ MORE

Developing New Outcome Measures, Functional Biomarkers & Clinical Research Regulatory Frameworks for Disease-Modifying Therapeutics Across Neurodevelopmental & Rare, Genetic CNS Disorders With further clinical data emerging, drug development for rare CNS and neurodevelopmental disorders is advancing from hypotheticals to real-life clinical results, outcomes, and functional biomarkers; catapulting this critical field forwards to change patients’ lives. …

Welcome to the 2nd Rare CNS & Neurodevelopmental Drug Development Summit Read More »

We hold events across the world including London, Switzerland, Boston and Copenhagen focused on connecting life science and healthcare companies with the investors and partners they need to grow.  Inv€$tival Showcase offers up 5 incredible stages for Startups, Series A, B and Public Biotech, Medtech, Healthtech and Women’s Health companies. They’ll deliver news and deal …

CONNECTING LIFE SCIENCE & HEALTHCARE EXECUTIVES WITH CAPITAL & PARTNERS Read More »

Clinical data clear major test for the first precision neurodevelopmental disorders discovery platform, with a first application in Autism Spectrum Disorder (ASD) STALICLA, a Swiss clinical stage biotech company leading omics-based drug development for patients with neurodevelopmental disorders (NDDs), announced today the highly successful completion of the phase 1b trials for its lead drug candidate …

STALICLA completes successful phase 1b trials for the first precision medicine in autism spectrum disorder Read More »

We are very pleased to share the replay of STALICLA’s expert presentation at the first Neurodevelopmental Disorder Drug Development held in December. The first edition of the Neurodevelopmental Disorders Drug Development Summit was organized by Hanson Wade, a healthcare specialized initiative with the goal to accelerate progress within organizations and across industries. Their primary method …

STALICLA at the first NDD Summit in 2021 Read More »

We are very pleased to announce the publication of our review on the Heterogeneity in Fragile X Syndrome (FXS) issued in Frontiers in Psychiatry. This article was written within the scope of the recent collaboration between STALICLA DDS in Barcelona and DDU in Geneva.It highlights the need for precision medicine-based treatments in neurodevelopmental disorders, with …

Publication of our review on the Heterogeneity in Fragile X Syndrome Read More »

Dix jeunes pousses suisses intègrent le premier programme Venture Leaders dédié au secteur des biotechnologies et iront cet automne à la rencontre d’investisseurs internationaux et des leaders du secteur. Parmi ces start-up sélectionnées, notamment, par Venturelab et Swissnex, trois romandes: Alithea Genomics, Gnubiotics Sciences et Stalicla. READ MORE